New report identifies benefits and concerns regarding telehealth, provides recommendations for improving perceptions DENVER, Aug. 14, 2024 /PRNewswire/ -- The Office...
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,...
IRVING, Texas, Aug. 13, 2024 /PRNewswire/ -- The N2 Company (N2) recently launched two groundbreaking monthly magazines, Salute and Uniquely You,...
TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)...
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3...
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program...
The CDC has reported an estimated 385,000 incidents of needlestick and sharps-related injuries among healthcare workers annually in the U.S.HOUSTON,...
WASHINGTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The American Foundation for the Blind (AFB) has announced that Kim Charlson and...
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address...
DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the...
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
MIAMI, July 25, 2024 /PRNewswire/ -- NAVIGANTIS Inc. announced today that it has closed a $12 million Series A financing led...
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and...
Speech Recognition Startup Announces New Program for Speech Pathologists and Other Therapy Professionals to Expand the Impact of its Inclusive Voice AI...